Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1Phase 1/2 1

Status

Recruiting 3Active not recruiting 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 4

Conditions

Breast Neoplasms 16Stomach Neoplasms 8Rectal Neoplasms 8Colorectal Neoplasms 7Triple Negative Breast Neoplasms 6Neoplasm Metastasis 6Adenocarcinoma Of Esophagus 6Adenocarcinoma 6Parkinson Disease 4, Autosomal Dominant Lewy Body 4Pancreatic Neoplasms 4Esophageal Neoplasms 4Nasopharyngeal Carcinoma 3Esophageal Squamous Cell Carcinoma 2Carcinoma 2Biliary Tract Neoplasms 2Anus Neoplasms 2Advanced Solid Tumour 2Solid Tumors 1Peritoneal Neoplasms 1Neoplasms 1HIV Infections 1HER2-positive Gastric Cancer 1HER2-positive Breast Cancer 1Colorectal Cancer Metastatic 1Colonic Neoplasms 1Clinical Stage I Gastric Cancer AJCC v8 1Clinical Stage I Esophageal Adenocarcinoma AJCC v8 1Anal Canal Carcinoma 1

Interventions

Oxaliplatin 7Fluorouracil 7pembrolizumab 6Leucovorin 5Specimen Handling 4Cisplatin 4Capecitabine 4patritumab deruxtecan 3Trastuzumab 3Radiation 3Paclitaxel 3Nivolumab 3durvalumab 2Surgical Procedures, Operative 2Ramucirumab 2Radiotherapy 2Pemetrexed 2Magnetic Resonance Spectroscopy 2Irinotecan 2Immunotherapy 2Exercise 2Drug Therapy 2Carboplatin 2zolbetuximab 1zanidatamab 1ulixertinib 1trastuzumab deruxtecan 1trastuzumab biosimilar HLX02 1trametinib 1tislelizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Esophageal Neoplasms × Capecitabine × 30 days × Clear all
NCT07431281 2026-05-27

Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2

AstraZeneca

Phase 3 Recruiting
2,130 enrolled
Gastrointestinal

Adenocarcinoma Of Esophagus, Adenocarcinoma, Esophageal Neoplasms, Stomach Neoplasms

NCT06469944 2026-05-26

MK-3475-06C

Merck Sharp & Dohme LLC

Phase 1/2 Recruiting
160 enrolled
Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Neoplasms

NCT05152147 2026-05-19

HERIZON-GEA-01

Jazz Pharmaceuticals

Phase 3 Active not recruiting
920 enrolled
Gastrointestinal

Adenocarcinoma Of Esophagus, Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Neoplasms, Stomach Neoplasms

NCT04379596 2026-05-13

DG-03

AstraZeneca

Phase 2 Recruiting
450 enrolled
Gastrointestinal

Adenocarcinoma, Carcinoma, Esophageal Neoplasms, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡